Adolescents with nicotine dependence may benefit from bupropion, whether or not they have comorbid attention-deficit hyperactivity disorder, said Dr. Himanshu P. Upadhyaya and colleagues at the Medical University of South Carolina, Charleston.
Bupropion slow release (SR) has been…
SCOTTSDALE, ARIZ. — Providing counseling on smoking cessation did not boost quit rates in patients being treated with bupropion SR, Danielle E. McCarthy reported in a poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
She and her colleagues recruited 463 adults who reported smoking at least 10 cigarettes per day and wanted to quit. Half the participants were female, and the mean age was 39 years.
The…
The Patient
You have a patient who suffers from schizophrenia. Positive symptoms have been well controlled with an antipsychotic for several months. He requests alleviation of his nicotine habit. You consider bupropion, but, knowing the mechanism of action of bupropion, you are concerned that positive symptoms may be exacerbated.
The Question
What is the risk of exacerbating positive…
BAL HARBOUR, FLA. — Extended-release bupropion appears to be a safe and effective treatment for adults with attention-deficit hyperactivity disorder, with more than 50% of patients experiencing at least a 30% reduction in core symptoms while on the drug, Dr. Joseph Horrigan reported in a poster at the annual meeting of the American Neuropsychiatric Association.
About 40%-70% of children with attention-deficit hyperact…
Bupropion may not be as good as editorial implies
EDITOR–Britton and Jarvis give a surprisingly uncritical welcome to bupropion.[1] Although Jorenby et al did find that 30% of patients who took bupropion were still non-smokers after 12 months (point prevalence data), these volunteers must have been highly motivated as 12-15% of those who took the placebo successfully stopped smoking.[2] There are no studies showing that bupropi…
